(Alliance News) - Syncona Ltd on Wednesday noted positive trial results for a portfolio company's gene therapy aimed at treating people with Gaucher's disease.
The global gaucher and pompe diseases enzyme replacement therapy (ERT) market is poised for remarkable growth, with projections indicating a surge from USD 3.3 billion in 2023 to an impressive USD 6.2 ...
We now introduce an algorithm called Root Causal Strength using Perturbations (RCSP) that discovers the surrogate ancestors of each variable using Perturb-seq and then computes the RCS of each ...